← Leaderboards
John Thomas Poirier
Sloan-Kettering Inst Can Research
$4,490,380
Attributed
$6,944,307
Total exposure
5
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.5M · FY2017–25$2.5M$1.9M$1.3M$625K$0
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$10,732,263 · 6
By mechanism
P01$4,908,544 · 3
R01$3,084,380 · 1
U01$2,739,339 · 2
Top collaborators
- Charles M Rudin7 shared
- Jason S Lewis4 shared
- Tony Tung Huang2 shared
- Wolfgang Weber1 shared
Most similar at Sloan-Kettering Inst Can Research
Same institution · by research overlap
- Richard N Kolesnick$17,601,323
- Jason S Lewis$26,024,327
- Nancy Y Lee$8,718,881
- Brian Matthew Zeglis$6,881,872
- Yelena Y Janjigian$1,716,445
Others in their field
Other Emerging Leaders on “Tumor”
- Leonard Freedman · Leidos Biomedical Research, Inc.$360,535,780
- Lynn Briscoe · Leidos Biomedical Research, Inc.$120,794,323
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$105,180,681
- Leonard Freedmand · Leidos Biomedical Research, Inc.$78,762,245
- Connie Suders · Leidos Biomedical Research, Inc.$67,882,919
- Gautam (george) Mitra · Leidos Biomedical Research, Inc.$53,523,213
Research focus
TumorMalignant NeoplasmsMolecularProteinsIn VivoCell LineTargeted TreatmentResponseNovel TherapeuticsMalignant Neoplasm Of LungNovel Therapeutic InterventionBaseClinical TrialsExtensive StageLabelUnited StatesXenograft ProcedureDiagnosisFda ApprovedDeferoxamineCell SurfaceDesignDna DamageImage
Grant awards (18)
Investigating and Targeting Replication Stress in Small Cell Lung Cancer$1,893,978
P01 · FY2025 · CA
Replication Stress Sensing and Signaling Defects in SCLC$350,490
P01 · FY2025 · CA · contact PI
SCLC Model Generation and Therapeutic Analysis$209,804
P01 · FY2025 · CA · contact PI
Investigating and Targeting Replication Stress in Small Cell Lung Cancer$1,893,978
P01 · FY2024 · CA
Replication Stress Sensing and Signaling Defects in SCLC$350,490
P01 · FY2024 · CA · contact PI
SCLC Model Generation and Therapeutic Analysis$209,804
P01 · FY2024 · CA · contact PI
Immuno-PET imaging of high-grade neuroendocrine lung tumors using 89Zrrovalpituzumab, a DLL3-targeting monoclonal antibody$939,811
R01 · FY2021 · CA · contact PI
Clinical development of a DLL3-targeted theranostic for small cell lung cancer$335,437
U01 · FY2021 · CA · contact PI
Immuno-PET imaging of high-grade neuroendocrine lung tumors using 89Zrrovalpituzumab, a DLL3-targeting monoclonal antibody$367,402
R01 · FY2020 · CA · contact PI
Clinical development of a DLL3-targeted theranostic for small cell lung cancer$351,777
U01 · FY2020 · CA · contact PI
Immuno-PET imaging of high-grade neuroendocrine lung tumors using 89Zr-rovalpituzumab, a DLL3-targeting monoclonal antibody$630,572
R01 · FY2019 · CA · contact PI
Identification and validation of synthetic lethality in KRAS mutant lung adenocarcinoma patient derived xenografts$463,415
U01 · FY2019 · CA
Preclinical development of a DLL3-targeted theranostic for small cell lung cancer$323,585
U01 · FY2019 · CA · contact PI
Immuno-PET imaging of high-grade neuroendocrine lung tumors using 89Zr-rovalpituzumab, a DLL3-targeting monoclonal antibody$699,927
R01 · FY2018 · CA · contact PI
Preclinical development of a DLL3-targeted theranostic for small cell lung cancer$339,331
U01 · FY2018 · CA · contact PI
Identification and validation of synthetic lethality in KRAS mutant lung adenocarcinoma patient derived xenografts$570,759
U01 · FY2017 · CA
Immuno-PET imaging of high-grade neuroendocrine lung tumors using 89Zr-rovalpituzumab, a DLL3-targeting monoclonal antibody$446,668
R01 · FY2017 · CA · contact PI
Preclinical development of a DLL3-targeted theranostic for small cell lung cancer$355,035
U01 · FY2017 · CA · contact PI